CHAMGAP
MethodologyVerdictsExplanations (KO)Evidence CheckCitation KitMonitoring

Dry-eye combination capsule · Evidence Check for reduced artificial-tear use

Select a review item to see its details.
Required evidence, verification status and materials actually read
ItemAVerification statusBReading scopeCReview itemDCurrent findingsEWhy unverifiedFRequired materials and conditionsGFurther research
1 Partly verified Full text not readStored summary read N01 · Comparative efficacy: finished product and selected endpointWhat are the original wording and subclaim verdict for artificial-tear use?Required
The original claim is reduced artificial-tear use, grade D, with the note that the follow-up between-group P=0.562. The parent is C with 50 points for tear volume/OSDI.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Distinguish selected-row grade/note from the parent verdict
Present artificial-tear use separately from tear-volume/symptom verdicts
2 Partly verified Full text not readStored summary read N02 · Comparative efficacy: finished product and selected endpointWhich trial directly reported the selected use outcome?Required
Artificial-tear-use P=0.562 belongs to the 2024 four-center US follow-up. The 2021 representative trial treated Schirmer and OSDI as coprimary outcomes.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Trial-specific original outcomes for the 2021 representative and 2024 follow-up trials
Separate different trials of the same formulation and their direct outcomes
3 Partly verified Full text not readStored summary read N03 · Comparative efficacy: finished product and selected endpointAre the follow-up population and applicability verified?Required
The 2024 four-center US follow-up records 155 randomized and 116 analyzed.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Follow-up dry-eye eligibility, baseline, severity and centers
Show recruitment-population differences between 2021 and the follow-up
4 Partly verified Full text not readStored summary read N04 · Comparative efficacy: finished product and selected endpointWhat are the study identity and ingredient combination?Required
The preserved study capsule combines lutein 20 mg, zeaxanthin 4 mg, curcuminoids 200 mg and vitamin D3 600 IU; the follow-up is described as the same formulation.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Fixed combination and product/exposure specifications for each trial
Distinguish the fixed finished product from individual-ingredient efficacy and other formulations
5 Partly verified Full text not readStored summary read N05 · Comparative efficacy: finished product and selected endpointAre placebo composition and trial-specific comparators distinguished?Required
The 2021 representative trial compared 30 appearance-matched soybean-oil placebo participants with 30 product participants. The follow-up was also double-blind and placebo-controlled.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Active/placebo composition, appearance, exposure and blinding
Show actual comparator conditions separately for each trial
6 Unverified Full text not readStored summary read N06 · Comparative efficacy: finished product and selected endpointWhat are the units and definition of artificial-tear use?Required
The preserved follow-up outcome only states artificial-tear use.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Original definitions of frequency, volume, days, people or user proportion
Present use units, aggregation and person denominators
7 Unverified Full text not readStored summary read N07 · Comparative efficacy: finished product and selected endpointAre baseline, group-specific final values and changes available?Required
The preserved information for the selected outcome is follow-up between-group P=0.562.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Group-specific original baseline, day-56 and change values for use
Separate use quantities from values/changes in other outcomes
8 Partly verified Full text not readStored summary read N08 · Comparative efficacy: finished product and selected endpointAre between-group use effects and confidence intervals provided?Required
The follow-up between-group use result, P=0.562, was described as null and was not counted as a benefit.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Use differences, ratios, effect scales, CIs and tests
Present the original test alongside missing effects/intervals
9 Unverified Full text not readStored summary read N09 · Comparative efficacy: finished product and selected endpointWhat prespecified outcome hierarchy applies to use?Required
Preserved follow-up evidence lists Schirmer and OSDI outcomes and mentions artificial-tear use separately in its results.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Primary, secondary or exploratory use outcome, plans and multiplicity
Distinguish primary/secondary/exploratory outcomes and the use-analysis hierarchy
10 Partly verified Full text not readStored summary read N10 · Comparative efficacy: finished product and selected endpointAre the measurement period and repeated units for use verified?Required
Follow-up tear-volume/symptom assessments are recorded at day 56. Use appears in the same report, but its exact observation window is absent from the summary.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Baseline/day-56 use observation windows, records and repeated-measure handling
Distinguish report assessment timing from actual use-observation windows
11 Unverified Full text not readStored summary read N11 · Comparative efficacy: finished product and selected endpointWhat policies governed permitted, rescue or changed artificial tears?Required
The summary provides a use comparison but lacks details of permission, rescue, prescribing or participant-choice policies.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Permitted adjunctive care, products, rescue, changes and recording rules in both groups
Distinguish adjunctive-care policy/actual use from the scope of product effects
12 Partly verified Full text not readStored summary read N12 · Comparative efficacy: finished product and selected endpointAre follow-up allocation, analysis and withdrawal denominators distinguished?Required
Follow-up evidence records 155 randomized and 116 analyzed.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Group-specific flow and exclusion reasons for 155 randomized and 116 analyzed
Show randomized, analyzed and use-observation denominators separately
13 Partly verified Full text not readStored summary read N13 · Comparative efficacy: finished product and selected endpointWas representative-trial complete-case analysis transferred to the follow-up?Required
In 2021, 60 were randomized (30/30) with 59 in complete-case analysis. The follow-up separately had 155 randomized and 116 analyzed.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Original/follow-up analysis populations, denominators and missingness
Distinguish each recruitment population and original analysis method
14 Partly verified Full text not readStored summary read N14 · Comparative efficacy: finished product and selected endpointWhat is the scope of randomization, concealment and blinded use measurement?Required
The follow-up is recorded as a multicenter double-blind placebo-controlled randomized trial.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Follow-up allocation, measurement, artificial-tear records and blinding
Distinguish design labels from actual implementation/use-measurement limitations
15 Partly verified Full text not readStored summary read N15 · Comparative efficacy: finished product and selected endpointDo positive OSDI/Schirmer results mean reduced artificial-tear use?Required
Representative-trial OSDI between-group P=0.0001 and Schirmer P<0.0001; both follow-up measures P<0.001. Artificial-tear use is separately null, P=0.562.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Outcome-specific direct results for symptoms, tear volume and adjunctive-care use
Show distinct outcomes alongside the selected null result
16 Partly verified Full text not readStored summary read N16 · Comparative efficacy: finished product and selected endpointWere representative OSDI baseline/final values converted into use quantities?Required
Representative OSDI values are product 30.10±4.88→17.09±4.85 and placebo 32.54±5.06→31.00±7.18.
R01
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Distinguish scales/units and within-group/between-group estimands
Separate symptom scales from adjunctive-care use quantities
17 Partly verified Full text not readStored summary read N17 · Comparative efficacy: finished product and selected endpointAre clinically important test/symptom differences and use-reduction thresholds the same?Required
The original summary says prespecified clinically important Schirmer-mm/OSDI thresholds and tabled 95% CIs were absent.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Use-outcome importance/interpretation criteria and direct intervals
Distinguish test/symptom thresholds from direct use-outcome criteria
18 Partly verified Full text not readStored summary read N18 · Comparative efficacy: finished product and selected endpointAre registration identifiers and external plans distinguished?Required
The 2021 identifier is CTRI/2021/01/030493; the follow-up identifier is NCT05481450.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Representative CTRI/follow-up NCT and trial-specific plans/history
Distinguish trial identifiers from actual reading/prespecified plans
19 Partly verified Full text not readStored summary read N19 · Comparative efficacy: finished product and selected endpointDoes the same-formulation follow-up mean the same participants or independent-company replication?Required
The representative single-center Indian trial had 60 participants; the four-center US follow-up had 155 in a separate study population. The original narrative describes shared company development/funding and no replication by independent investigators/funders.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Trial populations, centers, reports, funding and investigator links
Distinguish separate recruitment populations from funding independence/replication scope
20 Partly verified Full text not readStored summary read N20 · Comparative efficacy: finished product and selected endpointWas the fixed combination extended to single ingredients or other combinations?Required
The original advertising interpretation concerns a fixed four-ingredient combination and says it cannot be extended to lutein, curcumin or vitamin D alone, or to other combinations.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Direct finished-product, ingredient and formulation comparisons
Preserve the applicability of the fixed-combination question
21 Unverified Full text not readStored summary read N21 · Comparative efficacy: finished product and selected endpointDoes short-term use mean long-term adjunctive-care/disease-management benefit?Required
Both preserved trials concern day 56/eight weeks; the selected use result is null in the follow-up report.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Direct follow-up of post-discontinuation use, long-term symptoms and clinical outcomes
Distinguish short-term use/tests/symptoms from gaps in long-term direct outcomes
22 Partly verified Full text not readStored summary read N22 · Comparative efficacy: finished product and selected endpointAre representative-trial funding, products, formulation development and employee authors distinguished?Required
In 2021, OmniActive supported the trial, manufactured/supplied product and matched placebo, and participated in formulation development. Priyanka Radkar, Abhijeet Morde, Deshanie Rai and Muralidhara Padigaru were employees.
R01
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
OmniActive support/manufacturing/supply/development/author relationships
Show support separately from manufacturing/development/employee relationships
23 Partly verified Full text not readStored summary read N23 · Comparative efficacy: finished product and selected endpointAre follow-up trial costs, publication fees, medical writing and editorial support separated?Required
Original follow-up wording attributes trial costs to OmniActive and publication fees/medical-writing/editorial support to Bausch + Lomb.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Item-specific OmniActive and Bausch + Lomb roles
Record trial operating costs separately from writing/publication support
24 Partly verified Full text not readStored summary read N24 · Comparative efficacy: finished product and selected endpointAre follow-up employee authors and advisory-board relationships distinguished?Required
Follow-up AM, DR and MP are recorded as OmniActive employees; RR and KB as Bausch + Lomb employees; NG, JG, JP and LP as Bausch + Lomb advisory-board members.
R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Author-specific company, employment, advisory and contribution relationships
Show employee relationships separately from advisory/individual roles
25 Unverified Full text not readStored summary read N25 · Comparative efficacy: finished product and selected endpointWere all analysis, data and publication controls described as verified?Required
Some support, product, development, writing, editorial and author relationships are preserved.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Trial-specific outsourced analysis, data rights, responsibility and publication roles
Distinguish known involvement from unverified roles
26 Partly verified Full text not readStored summary read N26 · Supplementary harm evidenceWhat actual trial scope underlies safety-collection wording?Supplementary
The parent safety summary says hematology, chemistry, vital signs, physical examinations and AEs were assessed, with no safety issues or serious events reported.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Hematology, chemistry, vital signs, examinations, AEs and group-specific tables
Distinguish safety-narrative scope from trial-specific observation denominators
27 Unverified Full text not readStored summary read N27 · Supplementary harm evidenceAre long-term/rare harms and soybean-oil comparator safety verified?Supplementary
Short-term preserved results and representative soybean-oil placebo specifications are available.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Long-term exposure, rare events and population/product-specific harms
Separate efficacy/use comparisons from long-term safety gaps
28 Partly verified Full text not readStored summary read N28 · Comparative efficacy: finished product and selected endpointIs actual summary reading distinguished from unread external materials?Required
The whole parent JSON was read; the two PubMed URLs are linked as original bibliography.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Bibliography, preserved JSON, abstract, full text, registration and plan statuses
Show summary reading separately from material-specific external nonreading
29 Partly verified Full text not readStored summary read N29 · Comparative efficacy: finished product and selected endpointAre original subclaim/parent history, production and user review distinguished?Required
Preserve complete KO/EN, axes, the 2026-08-26 evidence date, empty corrections/deliberation and the selected row. Preserve original pending/eligible flags as history.
R01 R02
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
KO/EN, axes, dates, corrections, original selection and freeze/application
Separate original verdict/corrections from condition freeze/application and user review
No items match your search or filter.

29 itemsWhat the statuses mean

Assessment scope

Stored-material review date
Not recorded
Original evidence cut-off
2026-08-26
Scope actually checked
Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean
This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population
The selected result concerns the 2024 four-center US dry-eye follow-up: 155 randomized, 116 analyzed. The 2021 Indian representative trial in 60 adults with mild/moderate dry eye is separate context.
Ingredient, formulation and route
Fixed lutein, zeaxanthin, curcumin and vitamin D3 combination capsule
Dose
Preserved study combination: lutein 20 mg, zeaxanthin 4 mg, curcuminoids 200 mg and vitamin D3 600 IU. Trial-specific details are unread; this is not dosing guidance.
Comparator
Follow-up placebo; the representative 2021 appearance-matched soybean-oil placebo is a separate specification.
Measured outcome
Between-group artificial-tear-use outcome; use units, direct effects, CIs and observation windows unverified. Distinguish from Schirmer/OSDI.
Duration
Both reports concern day 56/eight weeks; exact use-observation windows and post-discontinuation follow-up are unverified.
Questions outside this scope
No new research, effects, CIs, calculations, assessments, independent certification, participant totals or product/drug-use/dosing/treatment or adjunct-treatment reduction/discontinuation guidance is created

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Radkar P, et al. A Novel Multi-Ingredient Supplement Reduces Inflammation of the Eye and Improves Production and Quality of Tears in Humans. Ophthalmol Ther. 2021;10:581-599. PMID: 34129210.

PubMed

Material type
Preserved summary of trial-paper bibliography
Materials actually read
Summary read; external abstracts, full texts, registration and plans unread
Findings recorded in the stored summary
OSDI between-group P=0.0001; Schirmer between-group P<0.0001; 95% CI not reported
Record level
2021 representative Schirmer/OSDI context; direct artificial-tear-use values are absent from the summary.
Study overlap and independent replication
2021 Indian representative population; separate 2024 US follow-up recruitment population. The same formulation/company lineage does not merge them into one cohort or independent-company replication.
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Stored summarySummary readStored summary readSummary readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
External abstractNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
External full textNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
Original registrationNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
Protocol/SAPNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts

R02 · A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease. Front Ophthalmol. 2024. PMID: 38984118.

PubMed

Material type
Preserved summary of trial-paper bibliography
Materials actually read
Summary read; external abstracts, full texts, registration and plans unread
Findings recorded in the stored summary
Follow-up between-group P=0.562.
Record level
Direct artificial-tear use in the 2024 four-center US follow-up, P=.562; separate from positive test/symptom results.
Study overlap and independent replication
2021 Indian representative population; separate 2024 US follow-up recruitment population. The same formulation/company lineage does not merge them into one cohort or independent-company replication.
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Stored summarySummary readStored summary readSummary readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
External abstractNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
External full textNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
Original registrationNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts
Protocol/SAPNot readExternal material unreadNot readMaterial slot; no certification of external acquisition/reading/link checks or independent-trial counts

Report counts versus independent study counts

2021 Indian representative population; separate 2024 US follow-up recruitment population. The same formulation/company lineage does not merge them into one cohort or independent-company replication.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What are the original wording and subclaim verdict for artificial-tear use?
Required materials and conditions
Distinguish selected-row grade/note from the parent verdict
Conditions for verification
Distinguish selected-row grade/note from the parent verdict; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N02 · Which trial directly reported the selected use outcome?
Required materials and conditions
Trial-specific original outcomes for the 2021 representative and 2024 follow-up trials
Conditions for verification
Trial-specific original outcomes for the 2021 representative and 2024 follow-up trials; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N03 · Are the follow-up population and applicability verified?
Required materials and conditions
Follow-up dry-eye eligibility, baseline, severity and centers
Conditions for verification
Follow-up dry-eye eligibility, baseline, severity and centers; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N04 · What are the study identity and ingredient combination?
Required materials and conditions
Fixed combination and product/exposure specifications for each trial
Conditions for verification
Fixed combination and product/exposure specifications for each trial; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N05 · Are placebo composition and trial-specific comparators distinguished?
Required materials and conditions
Active/placebo composition, appearance, exposure and blinding
Conditions for verification
Active/placebo composition, appearance, exposure and blinding; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N06 · What are the units and definition of artificial-tear use?
Required materials and conditions
Original definitions of frequency, volume, days, people or user proportion
Conditions for verification
Original definitions of frequency, volume, days, people or user proportion; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N07 · Are baseline, group-specific final values and changes available?
Required materials and conditions
Group-specific original baseline, day-56 and change values for use
Conditions for verification
Group-specific original baseline, day-56 and change values for use; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N08 · Are between-group use effects and confidence intervals provided?
Required materials and conditions
Use differences, ratios, effect scales, CIs and tests
Conditions for verification
Use differences, ratios, effect scales, CIs and tests; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N09 · What prespecified outcome hierarchy applies to use?
Required materials and conditions
Primary, secondary or exploratory use outcome, plans and multiplicity
Conditions for verification
Primary, secondary or exploratory use outcome, plans and multiplicity; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N10 · Are the measurement period and repeated units for use verified?
Required materials and conditions
Baseline/day-56 use observation windows, records and repeated-measure handling
Conditions for verification
Baseline/day-56 use observation windows, records and repeated-measure handling; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N11 · What policies governed permitted, rescue or changed artificial tears?
Required materials and conditions
Permitted adjunctive care, products, rescue, changes and recording rules in both groups
Conditions for verification
Permitted adjunctive care, products, rescue, changes and recording rules in both groups; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N12 · Are follow-up allocation, analysis and withdrawal denominators distinguished?
Required materials and conditions
Group-specific flow and exclusion reasons for 155 randomized and 116 analyzed
Conditions for verification
Group-specific flow and exclusion reasons for 155 randomized and 116 analyzed; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N13 · Was representative-trial complete-case analysis transferred to the follow-up?
Required materials and conditions
Original/follow-up analysis populations, denominators and missingness
Conditions for verification
Original/follow-up analysis populations, denominators and missingness; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N14 · What is the scope of randomization, concealment and blinded use measurement?
Required materials and conditions
Follow-up allocation, measurement, artificial-tear records and blinding
Conditions for verification
Follow-up allocation, measurement, artificial-tear records and blinding; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N15 · Do positive OSDI/Schirmer results mean reduced artificial-tear use?
Required materials and conditions
Outcome-specific direct results for symptoms, tear volume and adjunctive-care use
Conditions for verification
Outcome-specific direct results for symptoms, tear volume and adjunctive-care use; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N16 · Were representative OSDI baseline/final values converted into use quantities?
Required materials and conditions
Distinguish scales/units and within-group/between-group estimands
Conditions for verification
Distinguish scales/units and within-group/between-group estimands; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N17 · Are clinically important test/symptom differences and use-reduction thresholds the same?
Required materials and conditions
Use-outcome importance/interpretation criteria and direct intervals
Conditions for verification
Use-outcome importance/interpretation criteria and direct intervals; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N18 · Are registration identifiers and external plans distinguished?
Required materials and conditions
Representative CTRI/follow-up NCT and trial-specific plans/history
Conditions for verification
Representative CTRI/follow-up NCT and trial-specific plans/history; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N19 · Does the same-formulation follow-up mean the same participants or independent-company replication?
Required materials and conditions
Trial populations, centers, reports, funding and investigator links
Conditions for verification
Trial populations, centers, reports, funding and investigator links; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N20 · Was the fixed combination extended to single ingredients or other combinations?
Required materials and conditions
Direct finished-product, ingredient and formulation comparisons
Conditions for verification
Direct finished-product, ingredient and formulation comparisons; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N21 · Does short-term use mean long-term adjunctive-care/disease-management benefit?
Required materials and conditions
Direct follow-up of post-discontinuation use, long-term symptoms and clinical outcomes
Conditions for verification
Direct follow-up of post-discontinuation use, long-term symptoms and clinical outcomes; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N22 · Are representative-trial funding, products, formulation development and employee authors distinguished?
Required materials and conditions
OmniActive support/manufacturing/supply/development/author relationships
Conditions for verification
OmniActive support/manufacturing/supply/development/author relationships; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N23 · Are follow-up trial costs, publication fees, medical writing and editorial support separated?
Required materials and conditions
Item-specific OmniActive and Bausch + Lomb roles
Conditions for verification
Item-specific OmniActive and Bausch + Lomb roles; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N24 · Are follow-up employee authors and advisory-board relationships distinguished?
Required materials and conditions
Author-specific company, employment, advisory and contribution relationships
Conditions for verification
Author-specific company, employment, advisory and contribution relationships; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N25 · Were all analysis, data and publication controls described as verified?
Required materials and conditions
Trial-specific outsourced analysis, data rights, responsibility and publication roles
Conditions for verification
Trial-specific outsourced analysis, data rights, responsibility and publication roles; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N26 · What actual trial scope underlies safety-collection wording?
Required materials and conditions
Hematology, chemistry, vital signs, examinations, AEs and group-specific tables
Conditions for verification
Hematology, chemistry, vital signs, examinations, AEs and group-specific tables; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Supplementary
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N27 · Are long-term/rare harms and soybean-oil comparator safety verified?
Required materials and conditions
Long-term exposure, rare events and population/product-specific harms
Conditions for verification
Long-term exposure, rare events and population/product-specific harms; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Supplementary
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N28 · Is actual summary reading distinguished from unread external materials?
Required materials and conditions
Bibliography, preserved JSON, abstract, full text, registration and plan statuses
Conditions for verification
Bibliography, preserved JSON, abstract, full text, registration and plan statuses; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
N29 · Are original subclaim/parent history, production and user review distinguished?
Required materials and conditions
KO/EN, axes, dates, corrections, original selection and freeze/application
Conditions for verification
KO/EN, axes, dates, corrections, original selection and freeze/application; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Requirement and applicability
Required
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.
Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle
Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review
Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle
Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review
Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle
Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review
Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle
Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review
Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle
Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review
Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited
What the statuses mean
Partly verified
Some information exists in the preserved review summary; detailed original materials remain unverified. This does not certify a passed review or clinical efficacy.
Unverified
Detailed materials for the selected condition could not be established within the stored scope; this does not mean zero effect, zero studies or safety
Review incomplete
Review of existing content incomplete
Met
Use only within the relevant conditions after existing content review; no automatic designation in this preparation
Not reported
Distinguish only within materials actually read; do not turn unread external materials into unreported findings
Inaccessible
Not applied during this preparation because actual access was not tested
Not applicable
Use with a reason for non-applicability based on an explicit question boundary
Conflicting data
Judge after actual material comparison; review was not performed during this preparation
Insufficient evidence for the conditions
Do not use as a clinical grade encompassing currently unread materials

Change history

2026-10-12 · Public page/material version 1.0

Public pages and materials were created from the existing 29 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What are the original wording and subclaim verdict for artificial-tear use?

Current findings
The original claim is reduced artificial-tear use, grade D, with the note that the follow-up between-group P=0.562. The parent is C with 50 points for tear volume/OSDI.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Selected-row score, status and axes are absent. Do not transfer parent C, 50 points or E+ into scores/effects for reduced artificial-tear use.
Required materials and conditions
Distinguish selected-row grade/note from the parent verdict
Materials to obtain first
Selected row and original parent assessment
Further research
Present artificial-tear use separately from tear-volume/symptom verdicts
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Distinguish selected-row grade/note from the parent verdict; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N02 · Which trial directly reported the selected use outcome?

Current findings
Artificial-tear-use P=0.562 belongs to the 2024 four-center US follow-up. The 2021 representative trial treated Schirmer and OSDI as coprimary outcomes.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not copy positive 2021 P values or its 60-participant denominator as direct artificial-tear-use results. Use results in 2021 are unverified in the summary.
Required materials and conditions
Trial-specific original outcomes for the 2021 representative and 2024 follow-up trials
Materials to obtain first
Trial-specific original use, symptom and test-result tables
Further research
Separate different trials of the same formulation and their direct outcomes
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Trial-specific original outcomes for the 2021 representative and 2024 follow-up trials; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N03 · Are the follow-up population and applicability verified?

Current findings
The 2024 four-center US follow-up records 155 randomized and 116 analyzed.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Detailed follow-up eligibility, severity, ages and baseline use are absent from the summary. Do not automatically copy 2021 Indian mild/moderate eligibility to the follow-up.
Required materials and conditions
Follow-up dry-eye eligibility, baseline, severity and centers
Materials to obtain first
Follow-up eligibility, baseline characteristics and center materials
Further research
Show recruitment-population differences between 2021 and the follow-up
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Follow-up dry-eye eligibility, baseline, severity and centers; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N04 · What are the study identity and ingredient combination?

Current findings
The preserved study capsule combines lutein 20 mg, zeaxanthin 4 mg, curcuminoids 200 mg and vitamin D3 600 IU; the follow-up is described as the same formulation.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
This preserves study identity and is not dosing guidance. Exact products, batches and schedules in each trial are externally unread; do not isolate ingredient effects.
Required materials and conditions
Fixed combination and product/exposure specifications for each trial
Materials to obtain first
Trial-specific product, formulation and exposure specifications
Further research
Distinguish the fixed finished product from individual-ingredient efficacy and other formulations
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Fixed combination and product/exposure specifications for each trial; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N05 · Are placebo composition and trial-specific comparators distinguished?

Current findings
The 2021 representative trial compared 30 appearance-matched soybean-oil placebo participants with 30 product participants. The follow-up was also double-blind and placebo-controlled.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Detailed follow-up placebo specifications, batches and blinding implementation are externally unread. Do not copy all representative-trial placebo conditions to the follow-up.
Required materials and conditions
Active/placebo composition, appearance, exposure and blinding
Materials to obtain first
Trial-specific placebo/active specifications and blinding materials
Further research
Show actual comparator conditions separately for each trial
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Active/placebo composition, appearance, exposure and blinding; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N06 · What are the units and definition of artificial-tear use?

Current findings
The preserved follow-up outcome only states artificial-tear use.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Exact units, denominators and assessment for drop counts, frequency, product volume, days of use or user proportion are absent from the summary. Do not invent units or a reduction amount.
Required materials and conditions
Original definitions of frequency, volume, days, people or user proportion
Materials to obtain first
Original use-outcome definition and collection tools
Further research
Present use units, aggregation and person denominators
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Original definitions of frequency, volume, days, people or user proportion; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N07 · Are baseline, group-specific final values and changes available?

Current findings
The preserved information for the selected outcome is follow-up between-group P=0.562.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Group-specific use baseline, final values and changes are absent from the summary. Do not convert OSDI or Schirmer numbers into use quantities.
Required materials and conditions
Group-specific original baseline, day-56 and change values for use
Materials to obtain first
Original group-specific baseline/final/change tables for use
Further research
Separate use quantities from values/changes in other outcomes
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Group-specific original baseline, day-56 and change values for use; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N08 · Are between-group use effects and confidence intervals provided?

Current findings
The follow-up between-group use result, P=0.562, was described as null and was not counted as a benefit.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Exact between-group effect, direction, CI and effect scale are unverified. Do not turn the P value into zero effect, equivalence or no artificial-tear use at all.
Required materials and conditions
Use differences, ratios, effect scales, CIs and tests
Materials to obtain first
Direct comparative use effects and interval tables
Further research
Present the original test alongside missing effects/intervals
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Use differences, ratios, effect scales, CIs and tests; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N09 · What prespecified outcome hierarchy applies to use?

Current findings
Preserved follow-up evidence lists Schirmer and OSDI outcomes and mentions artificial-tear use separately in its results.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Prespecified use hierarchy, analysis plans and multiplicity handling are unread. Do not transfer positive coprimary outcomes into planning/success for use.
Required materials and conditions
Primary, secondary or exploratory use outcome, plans and multiplicity
Materials to obtain first
Follow-up protocol, SAP and outcome list
Further research
Distinguish primary/secondary/exploratory outcomes and the use-analysis hierarchy
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Primary, secondary or exploratory use outcome, plans and multiplicity; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N10 · Are the measurement period and repeated units for use verified?

Current findings
Follow-up tear-volume/symptom assessments are recorded at day 56. Use appears in the same report, but its exact observation window is absent from the summary.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not turn day 56 into invented days of use, cumulative drop counts or observation denominators. Do not add repeated measurements, eyes or people.
Required materials and conditions
Baseline/day-56 use observation windows, records and repeated-measure handling
Materials to obtain first
Use-record schedules, observation windows and repeated-measure handling
Further research
Distinguish report assessment timing from actual use-observation windows
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Baseline/day-56 use observation windows, records and repeated-measure handling; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N11 · What policies governed permitted, rescue or changed artificial tears?

Current findings
The summary provides a use comparison but lacks details of permission, rescue, prescribing or participant-choice policies.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not attribute use differences solely to the capsule or create artificial-tear reduction, discontinuation or replacement guidance.
Required materials and conditions
Permitted adjunctive care, products, rescue, changes and recording rules in both groups
Materials to obtain first
Follow-up artificial-tear/adjunctive-care rules and use tables
Further research
Distinguish adjunctive-care policy/actual use from the scope of product effects
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Permitted adjunctive care, products, rescue, changes and recording rules in both groups; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N12 · Are follow-up allocation, analysis and withdrawal denominators distinguished?

Current findings
Follow-up evidence records 155 randomized and 116 analyzed.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not label all 116 as completers, PP participants or the use-analysis denominator. Group denominators, reasons, missingness handling and use-outcome denominators are unverified; do not calculate their difference.
Required materials and conditions
Group-specific flow and exclusion reasons for 155 randomized and 116 analyzed
Materials to obtain first
Follow-up group-specific recruitment, analysis and use-outcome flow tables
Further research
Show randomized, analyzed and use-observation denominators separately
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Group-specific flow and exclusion reasons for 155 randomized and 116 analyzed; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N13 · Was representative-trial complete-case analysis transferred to the follow-up?

Current findings
In 2021, 60 were randomized (30/30) with 59 in complete-case analysis. The follow-up separately had 155 randomized and 116 analyzed.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not transfer 59/60, the complete-case approach or small eight-week-trial limitations as the exact follow-up analysis method. Do not add participants from the two trials.
Required materials and conditions
Original/follow-up analysis populations, denominators and missingness
Materials to obtain first
Participant-flow, analysis and missingness tables for both trials
Further research
Distinguish each recruitment population and original analysis method
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Original/follow-up analysis populations, denominators and missingness; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N14 · What is the scope of randomization, concealment and blinded use measurement?

Current findings
The follow-up is recorded as a multicenter double-blind placebo-controlled randomized trial.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Sequence generation, allocation concealment, blinding of use-record assessment and baseline balance are unread. Do not certify the design name or parent B2 as current review.
Required materials and conditions
Follow-up allocation, measurement, artificial-tear records and blinding
Materials to obtain first
Follow-up allocation/concealment, use-record and assessment methods
Further research
Distinguish design labels from actual implementation/use-measurement limitations
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Follow-up allocation, measurement, artificial-tear records and blinding; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N15 · Do positive OSDI/Schirmer results mean reduced artificial-tear use?

Current findings
Representative-trial OSDI between-group P=0.0001 and Schirmer P<0.0001; both follow-up measures P<0.001. Artificial-tear use is separately null, P=0.562.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not transfer positive symptom/test results into benefits for reduced adjunctive care, treatment replacement or reduced use.
Required materials and conditions
Outcome-specific direct results for symptoms, tear volume and adjunctive-care use
Materials to obtain first
Outcome-specific original symptom, test and use tables
Further research
Show distinct outcomes alongside the selected null result
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Outcome-specific direct results for symptoms, tear volume and adjunctive-care use; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N16 · Were representative OSDI baseline/final values converted into use quantities?

Current findings
Representative OSDI values are product 30.10±4.88→17.09±4.85 and placebo 32.54±5.06→31.00±7.18.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
OSDI scores differ from artificial-tear drops, frequency or days. Do not calculate values, changes or between-group differences, or copy them as reduced use.
Required materials and conditions
Distinguish scales/units and within-group/between-group estimands
Materials to obtain first
Scale-specific original values, units and estimand materials
Further research
Separate symptom scales from adjunctive-care use quantities
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Distinguish scales/units and within-group/between-group estimands; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01

N17 · Are clinically important test/symptom differences and use-reduction thresholds the same?

Current findings
The original summary says prespecified clinically important Schirmer-mm/OSDI thresholds and tabled 95% CIs were absent.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not fill actual artificial-tear-use importance criteria or CIs with that statement. Use importance and original intervals are separately unverified.
Required materials and conditions
Use-outcome importance/interpretation criteria and direct intervals
Materials to obtain first
Use-importance criteria, plans and effect intervals
Further research
Distinguish test/symptom thresholds from direct use-outcome criteria
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Use-outcome importance/interpretation criteria and direct intervals; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N18 · Are registration identifiers and external plans distinguished?

Current findings
The 2021 identifier is CTRI/2021/01/030493; the follow-up identifier is NCT05481450.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Original registrations, dates, amendment history and use plans are unread here. Do not merge the identifiers into one registration or independence certification.
Required materials and conditions
Representative CTRI/follow-up NCT and trial-specific plans/history
Materials to obtain first
Trial-specific registrations, protocols, SAPs and amendments
Further research
Distinguish trial identifiers from actual reading/prespecified plans
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Representative CTRI/follow-up NCT and trial-specific plans/history; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N19 · Does the same-formulation follow-up mean the same participants or independent-company replication?

Current findings
The representative single-center Indian trial had 60 participants; the four-center US follow-up had 155 in a separate study population. The original narrative describes shared company development/funding and no replication by independent investigators/funders.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not merge the same formulation into one cohort or certify two reports as unique-trial/independent-replication counts. Confirmed trial/participant totals are null.
Required materials and conditions
Trial populations, centers, reports, funding and investigator links
Materials to obtain first
Report, registration, population and company-lineage links
Further research
Distinguish separate recruitment populations from funding independence/replication scope
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Trial populations, centers, reports, funding and investigator links; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N20 · Was the fixed combination extended to single ingredients or other combinations?

Current findings
The original advertising interpretation concerns a fixed four-ingredient combination and says it cannot be extended to lutein, curcumin or vitamin D alone, or to other combinations.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not extend the selected artificial-tear null result into ingredient-specific zero effects or equivalence with other finished products.
Required materials and conditions
Direct finished-product, ingredient and formulation comparisons
Materials to obtain first
Direct ingredient/other-formulation comparisons
Further research
Preserve the applicability of the fixed-combination question
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Direct finished-product, ingredient and formulation comparisons; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N21 · Does short-term use mean long-term adjunctive-care/disease-management benefit?

Current findings
Both preserved trials concern day 56/eight weeks; the selected use result is null in the follow-up report.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not fill long-term reduced use, disease treatment, improved vision, treatment replacement or post-discontinuation durability with new claims.
Required materials and conditions
Direct follow-up of post-discontinuation use, long-term symptoms and clinical outcomes
Materials to obtain first
Long-term post-discontinuation adjunctive-care/clinical follow-up
Further research
Distinguish short-term use/tests/symptoms from gaps in long-term direct outcomes
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Direct follow-up of post-discontinuation use, long-term symptoms and clinical outcomes; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N22 · Are representative-trial funding, products, formulation development and employee authors distinguished?

Current findings
In 2021, OmniActive supported the trial, manufactured/supplied product and matched placebo, and participated in formulation development. Priyanka Radkar, Abhijeet Morde, Deshanie Rai and Muralidhara Padigaru were employees.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not copy all representative support/author identities to the follow-up. Complete contractual, data and publication rights are unread.
Required materials and conditions
OmniActive support/manufacturing/supply/development/author relationships
Materials to obtain first
Representative funding/product/development/COI/role specifications
Further research
Show support separately from manufacturing/development/employee relationships
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
OmniActive support/manufacturing/supply/development/author relationships; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01

N23 · Are follow-up trial costs, publication fees, medical writing and editorial support separated?

Current findings
Original follow-up wording attributes trial costs to OmniActive and publication fees/medical-writing/editorial support to Bausch + Lomb.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not mix publication/writing support with trial-cost funding or remove disclosed support. Outsourced analysis and data control are separately unverified.
Required materials and conditions
Item-specific OmniActive and Bausch + Lomb roles
Materials to obtain first
Follow-up funding, writing, editorial, publication and analysis-role disclosures
Further research
Record trial operating costs separately from writing/publication support
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Item-specific OmniActive and Bausch + Lomb roles; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N24 · Are follow-up employee authors and advisory-board relationships distinguished?

Current findings
Follow-up AM, DR and MP are recorded as OmniActive employees; RR and KB as Bausch + Lomb employees; NG, JG, JP and LP as Bausch + Lomb advisory-board members.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not expand initials into names absent from the original or turn advisory members into employees. Individual contributions/role details are unread.
Required materials and conditions
Author-specific company, employment, advisory and contribution relationships
Materials to obtain first
Follow-up author COI, affiliations and contributions
Further research
Show employee relationships separately from advisory/individual roles
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Author-specific company, employment, advisory and contribution relationships; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R02

N25 · Were all analysis, data and publication controls described as verified?

Current findings
Some support, product, development, writing, editorial and author relationships are preserved.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not certify unmentioned outsourced analysis, data control or other relationships as all absent or completely independent.
Required materials and conditions
Trial-specific outsourced analysis, data rights, responsibility and publication roles
Materials to obtain first
Complete trial-specific role/data/publication-right disclosures
Further research
Distinguish known involvement from unverified roles
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Trial-specific outsourced analysis, data rights, responsibility and publication roles; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N26 · What actual trial scope underlies safety-collection wording?

Current findings
The parent safety summary says hematology, chemistry, vital signs, physical examinations and AEs were assessed, with no safety issues or serious events reported.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Follow-up-specific event tables, group denominators, collection and withdrawal scope are externally unread. Do not turn this into all events zero in both trials or safety equivalence.
Required materials and conditions
Hematology, chemistry, vital signs, examinations, AEs and group-specific tables
Materials to obtain first
Trial-specific group safety, collection and exposure tables
Further research
Distinguish safety-narrative scope from trial-specific observation denominators
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Hematology, chemistry, vital signs, examinations, AEs and group-specific tables; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N27 · Are long-term/rare harms and soybean-oil comparator safety verified?

Current findings
Short-term preserved results and representative soybean-oil placebo specifications are available.
Verification status
Unverified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Do not fill absence of long-term/rare harms, safety for every population or safety equivalence with the comparator from short-term nonreporting.
Required materials and conditions
Long-term exposure, rare events and population/product-specific harms
Materials to obtain first
Long-term, product/population-specific harms and exposure materials
Further research
Separate efficacy/use comparisons from long-term safety gaps
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Long-term exposure, rare events and population/product-specific harms; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N28 · Is actual summary reading distinguished from unread external materials?

Current findings
The whole parent JSON was read; the two PubMed URLs are linked as original bibliography.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
External abstracts, full texts, registrations, protocols, SAPs, links and screens were not newly read/checked. Do not treat URLs as content/reading certification.
Required materials and conditions
Bibliography, preserved JSON, abstract, full text, registration and plan statuses
Materials to obtain first
Original reports, registrations and plans
Further research
Show summary reading separately from material-specific external nonreading
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
Bibliography, preserved JSON, abstract, full text, registration and plan statuses; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02

N29 · Are original subclaim/parent history, production and user review distinguished?

Current findings
Preserve complete KO/EN, axes, the 2026-08-26 evidence date, empty corrections/deliberation and the selected row. Preserve original pending/eligible flags as history.
Verification status
Partly verified
Materials actually read
Summary read; related external material unread
Why unverified
Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information
Keep content review incomplete with waiting inactive and completion marked false, new units 0 and independent confirmed totals unrecorded. The evidence date is not a new review date.
Required materials and conditions
KO/EN, axes, dates, corrections, original selection and freeze/application
Materials to obtain first
Original source, selected original row and production events
Further research
Separate original verdict/corrections from condition freeze/application and user review
Remaining uncertainty
External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification
KO/EN, axes, dates, corrections, original selection and freeze/application; preserve original values, direct observations, scope and gaps without creating new effects, verdicts, calculations or independence certification
Why this condition is needed
Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions
Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods
Retain the production copy of existing applied conditions and methodology links; this does not mean complete review of definitions or formal certification.

Related sources R01 R02